Can-Fite BioPharma (CANF) Competitors $0.65 0.00 (-0.11%) As of 09/5/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CANF vs. TNFA, AEON, EVOK, BCLI, ADXN, ADIL, CYCN, TSBX, CELZ, and VYNEShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include TNF Pharmaceuticals (TNFA), AEON Biopharma (AEON), Evoke Pharma (EVOK), Brainstorm Cell Therapeutics (BCLI), Addex Therapeutics (ADXN), Adial Pharmaceuticals (ADIL), Cyclerion Therapeutics (CYCN), Turnstone Biologics (TSBX), Creative Medical Technology (CELZ), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Its Competitors TNF Pharmaceuticals AEON Biopharma Evoke Pharma Brainstorm Cell Therapeutics Addex Therapeutics Adial Pharmaceuticals Cyclerion Therapeutics Turnstone Biologics Creative Medical Technology VYNE Therapeutics Can-Fite BioPharma (NYSE:CANF) and TNF Pharmaceuticals (NASDAQ:TNFA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability. Do analysts rate CANF or TNFA? Can-Fite BioPharma currently has a consensus price target of $14.50, suggesting a potential upside of 2,127.34%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Can-Fite BioPharma is more favorable than TNF Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00TNF Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CANF or TNFA more profitable? Can-Fite BioPharma's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Can-Fite BioPharmaN/A N/A N/A TNF Pharmaceuticals N/A -69.21%-33.98% Which has more volatility & risk, CANF or TNFA? Can-Fite BioPharma has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Does the media prefer CANF or TNFA? In the previous week, TNF Pharmaceuticals had 3 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 6 mentions for TNF Pharmaceuticals and 3 mentions for Can-Fite BioPharma. TNF Pharmaceuticals' average media sentiment score of 0.47 beat Can-Fite BioPharma's score of 0.33 indicating that TNF Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TNF Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders believe in CANF or TNFA? 21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, CANF or TNFA? Can-Fite BioPharma has higher revenue and earnings than TNF Pharmaceuticals. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCan-Fite BioPharma$560K4.12-$7.63M-$1.79-0.36TNF PharmaceuticalsN/AN/A-$23.36M-$231.00-0.01 SummaryCan-Fite BioPharma beats TNF Pharmaceuticals on 10 of the 14 factors compared between the two stocks. Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.31M$947.58M$5.79B$21.34BDividend YieldN/A4.84%6.71%3.50%P/E Ratio-0.361.1676.1529.63Price / Sales4.1226.86462.7249.06Price / CashN/A19.5636.9624.54Price / Book0.376.7311.484.55Net Income-$7.63M-$3.82M$3.29B$999.70M7 Day Performance3.10%0.54%1.27%0.58%1 Month Performance-5.02%12.25%7.94%5.66%1 Year Performance-70.81%28.10%62.94%17.40% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma2.9476 of 5 stars$0.65-0.1%$14.50+2,127.3%-72.0%$2.31M$560K-0.368Analyst ForecastShort Interest ↓TNFATNF PharmaceuticalsN/A$0.05-21.6%N/AN/A$8.63MN/A-0.026News CoverageAnalyst UpgradeStock SplitGap DownAEONAEON Biopharma3.2984 of 5 stars$0.73-5.9%$360.00+49,100.5%-98.7%$8.52MN/A4.075News CoverageShort Interest ↓EVOKEvoke Pharma0.0809 of 5 stars$5.45+3.0%N/A+33.6%$8.49M$10.25M-2.134BCLIBrainstorm Cell Therapeutics2.1744 of 5 stars$0.76+4.0%N/A-82.9%$8.38MN/A-0.2340Short Interest ↓ADXNAddex Therapeutics1.6594 of 5 stars$8.06-7.7%$30.00+272.4%-31.3%$8.37M$460K-23.6930ADILAdial Pharmaceuticals2.749 of 5 stars$0.38-2.3%$8.00+2,005.3%-65.8%$8.29MN/A-0.3620Short Interest ↓CYCNCyclerion Therapeutics1.214 of 5 stars$2.53-1.8%N/A-20.9%$8.24M$2M-3.4130Short Interest ↑TSBXTurnstone Biologics2.9098 of 5 stars$0.36flat$0.45+26.8%N/A$8.22M$19.31M-0.1782CELZCreative Medical Technology0.1756 of 5 stars$3.18+0.6%N/A-5.4%$8.21M$10K-1.005Positive NewsVYNEVYNE Therapeutics1.8456 of 5 stars$0.32-2.7%$6.25+1,850.1%-84.5%$8.16M$500K-0.3630 Related Companies and Tools Related Companies TNF Pharmaceuticals Alternatives AEON Biopharma Alternatives Evoke Pharma Alternatives Brainstorm Cell Therapeutics Alternatives Addex Therapeutics Alternatives Adial Pharmaceuticals Alternatives Cyclerion Therapeutics Alternatives Turnstone Biologics Alternatives Creative Medical Technology Alternatives VYNE Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CANF) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CANF Stock Alerts